Metraipolis › archive › dc_4bac46d65fa4

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single… — Europe PMC PMID:41583497

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41583497
DOI
10.3389/fimmu.2025.1710017
License (as archived)
solo-consultazione
Archived
2026-11-07T00:04:06.629Z
SHA-256 of the archived text
378ffd13f612a0b1189877d21882148567fb232ce9386ea368a9955fe9bbec73
Stable URL of this page
https://metraipolis.com/documento/dc_4bac46d65fa4

How to cite

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single… — Europe PMC PMID:41583497 — Europe PMC (en), https://europepmc.org/article/MED/41583497 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4bac46d65fa4 (Metraipolis archive dc_4bac46d65fa4, sha256 378ffd13f612a0b1189877d21882148567fb232ce9386ea368a9955fe9bbec73)
BibTeX
@misc{dc4bac46d65fa4,
  title = {Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single… — Europe PMC PMID:41583497},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41583497},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4bac46d65fa4; sha256 378ffd13f612a0b1189877d21882148567fb232ce9386ea368a9955fe9bbec73},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41583497. Agents can read the archived copy with the MCP tool read_document.